Sequences obtained for this study are available via the ENA database under the accession number: PRJEB28417.

Introduction {#sec005}
============

Humans coexist with trillions of microbes on their body surfaces, collectively referred to as microbiota. One of the key benefits these microbes confer to their host is colonization resistance (CR), i.e. protection against invasion and infection by pathogens. It is conceivable that during gut colonization, the pathogen has to compete with the resident intestinal microbiota for nutrients and binding sites (nutrient-niche hypothesis) \[[@pone.0206214.ref001], [@pone.0206214.ref002]\]. Yet, the mechanistic details underlying the protective effect by the microbiota have not been fully elucidated.

Several perturbations can disrupt colonization resistance. Antibiotic treatment can disturb the intestinal microbiota, predisposing the host to infections with enteric pathogens including *Salmonella* Typhimurium (*S*. Typhimurium) and *Clostridium difficile* in humans \[[@pone.0206214.ref003]\] and in a murine model \[[@pone.0206214.ref001], [@pone.0206214.ref004], [@pone.0206214.ref005]\]. Likewise, according to the nutrient-niche hypothesis, providing the ecosystem with an additional nutrient should also open new niches, which might reduce colonization resistance for certain pathogens. Effects of long-term and short-term (\< 1 day) perturbations might thereby differ since long-lasting interventions will trigger complex secondary responses of the gut ecosystem.

The disaccharide lactulose is used as a food ingredient (named galacto-fructose) \[[@pone.0206214.ref006], [@pone.0206214.ref007]\] and as a prescription or over-the-counter medication for constipation \[[@pone.0206214.ref008]\] or hepatic encephalopathy in individuals with liver cirrhosis \[[@pone.0206214.ref009]\]. The lactulose breath test uses lactulose to diagnose small intestinal bacterial overgrowth \[[@pone.0206214.ref010]\]. As lactulose cannot be absorbed during the passage through the host\'s small intestine \[[@pone.0206214.ref011]\], it reaches the large intestine where it enriches the nutrient pool available to the gut microbiota. After arrival, lactulose is fermented by certain gut microbiota members resulting in the production of short chain fatty acids (SCFA), hydrogen (H~2~) and methane \[[@pone.0206214.ref012], [@pone.0206214.ref013]\]. The production of these compounds explains the laxative properties and also the side effects (abdominal pain and bloating) of this drug. Based on these observations, it seems likely that the intake of lactulose might significantly alter nutrient availability in the colon and thereby change the colonic microbiota composition. Effects of short-term lactulose exposure on the gut microbiota have been insufficiently studied.

We hypothesized that lactulose may also promote gut luminal growth of Enterobacteriaceae like *S*. Typhimurium or *Escherichia coli* (*E*. *coli*). *E*. *coli* shares most metabolic requirements of *S*. Typhimurium and growth of *E*. *coli* in stool samples is considered a surrogate for favorable growth conditions of enteropathogens such as *S*. Typhimurium \[[@pone.0206214.ref014]\]. In contrast to *S*. Typhimurium, *E*. *coli* can grow on lactulose, i.e. by taking up and degrading this disaccharide. However, *E*. *coli* might also benefit directly or indirectly from the sugar monomers galactose and fructose, which are released upon degradation of lactulose by certain members of the gut microbiota \[[@pone.0206214.ref015], [@pone.0206214.ref016]\] or by fermentation products like H~2~. H~2~ can serve as an electron donor for *S*. Typhimurium and other Enterobacteriaceae \[[@pone.0206214.ref017]--[@pone.0206214.ref021]\]. Data in our murine model of *S*. Typhimurium colitis demonstrated significant attenuation of a *S*. Typhimurium mutant deficient in H~2~-metabolism during initial stages of infection \[[@pone.0206214.ref018]\]. H~2~ therefore constitutes a critical metabolic intermediate exploited by *S*. Typhimurium for efficient colonization of the large intestine \[[@pone.0206214.ref018]\].

These data from animal experiments raise the possibility that lactulose exposure might promote growth of intestinal pathogens also in humans. Since lactulose is frequently used in medical practice for instance for patients with advanced liver disease (see above), such a finding would have significant medical implications. However, the relevance of the mouse data has not been validated in humans.

Our study aims to test the hypothesis that the intake of lactulose can promote gut luminal growth of Enterobacteriaceae such as *E*. *coli* and *S*. Typhimurium. This effects might manifest rapidly since previous studies demonstrated alterations in microbiota composition within 24 hours after dietary interventions \[[@pone.0206214.ref022]--[@pone.0206214.ref025]\]. A single lactulose dose will allow monitoring direct effects of this intervention, avoiding the complexity of secondary physiological and microbiological compensatory responses upon long-term exposure.

In this study, we assessed short-term effects of lactulose intake on human volunteers using a single lactulose dose. We tested for preferential growth of Enterobacteriaceae (Enterobacteriaceae blooms) which would indicate increased risk for infection by Enterobacteriaceae in healthy individuals and by extrapolation in patients.

Experimental procedures {#sec006}
=======================

Sample size calculation {#sec007}
-----------------------

To test the primary hypothesis of our study that lactulose exposure would increase growth of *E*. *coli* (as a marker for Enterobacteriaceae) the following sample size calculation was performed: To be clinically relevant, the difference in *E*. *coli* counts after lactulose exposure compared to sucrose should be at least one order of magnitude. Bacteria concentrations were estimated to be normally distributed. In a conservative calculation, we estimated a bacteria concentration of 100'000 cfu/g with a standard deviation of 100'000 in the sucrose group and a bacteria concentration of 1'000'000 cfu/g with a standard deviation of 1'000'000 in the lactulose group. In a two-tailed unpaired analysis, a sample size of 30 individuals (15 in each group) would be required to detect this difference with a power of 90% at a significance level of 0.05 (Mann-Whitney U test).

Study participants {#sec008}
------------------

For this study, 32 healthy volunteers were recruited via advertising. Exclusion criteria were a history of intestinal surgery (except hernia repair, appendectomy or anorectal surgery), pregnancy, relevant gastrointestinal symptoms (i.e., symptoms that cannot be ignored), medical or psychiatric conditions requiring ongoing management or intake of medication affecting gastrointestinal function (for instance laxatives, opioids, non-steroidal anti-inflammatory drugs, proton pump inhibitors or antibiotics within the last 4 weeks). To ensure proper handling of stool samples only employees of ETH Zurich or Zurich University, familiar with freezing and storing samples at -80°C were recruited. All participants provided written informed consent and were compensated for their expenses. The first participant was included on the 30^th^ of January 2015, the last participant was included into the study at the 14^th^ of April 2015 and completed the study on 30^th^ of April 2015. No follow up was performed ([Fig 1](#pone.0206214.g001){ref-type="fig"}).

![Consort flow chart.](pone.0206214.g001){#pone.0206214.g001}

Participants were screened during an interview and epidemiological data, information regarding gastrointestinal function or symptoms, medical history, medication, gastrointestinal function and life style (vegan, vegetarian or Western diet, sport \[hours of exercise per week\], alcohol consumption, smoking) were recorded ([Table 1](#pone.0206214.t001){ref-type="table"}). Before the intervention day, participants fasted for 12h with only water allowed prior to the intervention.

10.1371/journal.pone.0206214.t001

###### Epidemiological and clinical characteristics of the study population.

BSS: Bristol stool scale; IQR: interquartile range.

![](pone.0206214.t001){#pone.0206214.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                            Sucrose                                         Lactulose
  ----------------------------------------- ----------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  **Number of participants**                15                                              17

  **Age**: median (IQR; range)              25 (23--28.5; 21--36)                           24 (22--31; 21--47)

  **Gender**: female n (%)                  9 (60%)                                         9 (53%)

  **Stool frequency**                                                                       

  every 2--3 days: n (%)                    2 (13%)                                         3 (18%)

  1x per day: n (%)                         10 (67%)                                        12 (70%)

  2-3x per day: n (%)                       3 (20%)                                         2 (12%)

  **Stool consistency (BSS)**                                                               

  median (IQR; range)                       4 (3--4; 3--7)                                  4 (3--4; 3--4)

  **Diet**                                                                                  

  Western diet                              15 (100%)                                       15 (88%)

  Vegetarian diet                           \-                                              2 (12%)

  **Non-smokers:** n (%)                    15 (100%)                                       17 (100%)[^a^](#t001fn001){ref-type="table-fn"}

  **Physical exercise per week (hours)**\   4 (3--5.5; 2--8)                                3 (2--5; 0--12)
  median (IQR; range)                                                                       

  **Medication:** Yes n (%)                 8 (53%)[^b^](#t001fn002){ref-type="table-fn"}   7 (41%)[^c^](#t001fn003){ref-type="table-fn"}

  **Ethnicity**                                                                             

  Caucasian: n (%)                          14 (93%)                                        14 (82%)

  Non-Caucasian: n (%)                      1 (7%)[^d^](#t001fn004){ref-type="table-fn"}    3 (18%)[^e^](#t001fn005){ref-type="table-fn"}^,^[^f^](#t001fn006){ref-type="table-fn"}^,^[^g^](#t001fn007){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Minimal nicotine consumption in one person (3--4 cigarettes/week)

^b^ 3x hormonal contraception, 1x thyroid hormone replacement, 3x ibuprofen

^c^ 3x hormonal contraception, 1each ibuprofen, paracetamol, thyroid hormone replacement

^d^ born in Vietnam, living in Switzerland for 2 years

^e^ parents from Sri Lanka, participant born in Switzerland

^f^ born in Turkey, living in Switzerland for 4 years

^g^ born in Cameroon, living in Switzerland for 3 years

Our study was approved by the Ethics committee of Zurich county (KEK-ZH 2014--0358) and registered at clinicaltrials.gov (NCT02397512).

Study design {#sec009}
------------

The participants were randomly assigned to two groups (<http://www.graphpad.com/quickcalcs/randomize1.cfm>) using the sealed envelope method and treated in a double blinded fashion. The control group (n = 15) received a sham treatment of 50 g sucrose (Migros, Zurich) dissolved in 200 ml water. The intervention group (n = 17) consumed a drink containing 50 g lactulose (Legendal 12g, Zambon, the Netherlands) dissolved in 200 ml water ([Fig 2](#pone.0206214.g002){ref-type="fig"}). H~2~ levels in parts per million (ppm) in expiratory air of participants were measured at 0 min (baseline), 15 min, 30 min, 60 min, 90 min, 120 min, and 180 min after the consumption of the respective sugar solution using the HydroCheck breath measuring device (Neomed Medizintechnik GmbH Üchtelhausen, Germany) ([Fig 2](#pone.0206214.g002){ref-type="fig"}). Methane content of expiratory air was recorded using Breath Collection Kit (BreathTracker SC, QuinTron USA). Due to technical issues, methane measurements could be performed only in the last 14 individuals included in our study. At all time points participants were asked to evaluate the strength of nausea, bloating, pain, stool alterations and borborygmi (bowel sounds) using a 4-point scale (1---no symptoms, 2---light symptoms which can be ignored \[i.e. will not be noticed if attention is shifted to another topic\], 3---marked symptoms which cannot be ignored \[i.e. will typically be noticed even if individual actively shifts attention to other topics\] but would not affect daily activity and 4---severe symptoms affecting daily activities. An additional questionnaire recorded bowel consistency (maximum Bristol stool scale, BSS) and frequency of bowel movements during 6 hours after the consumption of the respective sugar solution.

![Overview of the design of our study.\
32 healthy participants were randomly assigned to either the control group (sucrose) or to the experimental group (lactulose). Fecal samples were collected one day before treatment, one day after treatment and two weeks after treatment for further microbial analysis. On the day of treatment, hydrogen levels were measured in expiratory air at the indicated time points.](pone.0206214.g002){#pone.0206214.g002}

To assess effects on the resident gut microbiota, fecal samples were collected one day before, one day after, and two weeks after lactulose or sucrose exposure ([Fig 2](#pone.0206214.g002){ref-type="fig"}). Half of the fecal sample was stored in a test tube containing trypticase soy broth (Oxoid/ Thermo Fisher Diagnostics AG, Pratteln, Switzerland) with 15% (w/v) glycerol (Sigma-Aldrich, Buchs, Switzerland) \[[@pone.0206214.ref026]\]. This sample was used for the analysis of the colony forming units (CFU) per gram feces and the isolation of single bacterial strains. The other half of the fecal sample was stored in a test tube without any supplements and used for the analysis of microbiota composition. Within one hour after collection, samples were delivered by the participants and stored in a -80°C freezer provided by the investigators. To ensure proper handling of samples only individuals familiar with handling of -80°C freezers had been recruited (see inclusion criteria above) and importance of rapid sample transfer was emphasized to all individuals. Timely transfer of the fecal sample to the freezer within 30--60 min was confirmed by questionnaires to participants.

Microbiota quantification and isolation of Enterobacteriaceae by agar plating {#sec010}
-----------------------------------------------------------------------------

Fecal samples were transferred to Eppendorf tubes containing 500 μl of phosphate buffered saline (PBS) with tergitol (Sigma-Aldrich) and a sterile metal ball, weighed, and homogenized (1 min at 25 Hz, using a TissueLyser (Qiagen, Hombrechtikon, Switzerland). Differential plating on MacConkey agar plates (Oxoid) without any antibiotics allowed identification of bacterial population size (CFU; i.e. *E*. *coli*, *Salmonella* spp. and other Enterobacteriaceae) within the individual samples. In an attempt to capture the enterobacteriaceal diversity, several morphologically different colonies from each time point were picked and restreaked three times on new MacConkey agar plates. After restreaking, pure single colonies were picked and cultured in lysogeny broth (LB) for 10-12h at 37°C shaking (160 rpm). Bacterial cultures were stocked in peptone glycerol broth (peptone: Oxoid, glycerol: Sigma-Aldrich), shock frozen and stored at -80°C.

Antibiotic susceptibility testing {#sec011}
---------------------------------

Test antibiotics were chosen according to known genetic determinants of resistance \[[@pone.0206214.ref027]\]. Test tubes containing 2 ml LB media were inoculated with the isolated bacterial strains and incubated for 5h at 37°C shaking (160 rpm). Optical density (OD) 600 was measured and a fraction of the culture was used to inoculate new test tubes containing 2 ml LB media to obtain a final OD 600 of approximately 0.02. Liquid cultures were diluted 1:10 in sterile ddH~2~O and streaked with a cotton swab three times with 45° shifts on Mueller-Hinton agar to obtain a bacterial lawn of a density according to British Society for Antimicrobial Chemotherapy (BSAC) standards \[[@pone.0206214.ref028]\]. Antibiotic discs were placed on the agar using sterile tweezers, followed by incubation at 37°C for 18-20h. The diameter of the zone of inhibition was measured for each antibiotic and bacterial strains were classified as susceptible, intermediate, and resistant according to the Clinical and Laboratory Standards Institute (CLSI) \[[@pone.0206214.ref029]\].

16S rRNA gene analysis of isolated Enterobacteriaceae strains {#sec012}
-------------------------------------------------------------

For each bacterial strain, 50 μl of an overnight culture were centrifuged (5min, 8000 rpm), suspended in 100 μl sterile H~2~O and incubated at 99°C for 3 min. Genomic DNA was collected from supernatant after centrifugation (3min, 8000 rpm). 8 μl DNA was amplified by PCR in a 100 μl reaction mixture containing 10 μl buffer (5 PRIME PCR master kit), 5 U Taq polymerase (5 PRIME PCR master kit), 8 μl 2.5 mM dNTPs, 53 μl ddH~2~O and 10 μl of each forward primer (fD1: `5'-AGAGTTTGATCCTGGCTCAG-3'`) \[[@pone.0206214.ref030]\] and reverse primer (rP1: `5'-ACGGTTACCTTGTTAGCACTT-3'`) \[[@pone.0206214.ref031]\] diluted 1:10 in ddH~2~O (final primer concentration 1 μM). The amplification program consisted of an initial denaturation step of 5 min at 94°C; followed by 35 cycles of 1 min at 94°C, 1 min at 43°C, and 2 min at 72°C; and a final extension of 7 min at 72°C. A negative control was included in each batch of PCR reactions. Correct PCR product size was confirmed using agarose gel electrophoresis and ethidium bromide staining, DNA fragments were excised under UV light and extracted using the Wizard SV Gel and PCR Clean-Up System (Promega, Dübendorf, Switzerland).

Excised DNA fragments were sent for sequencing at Microsynth AG Balgach, Switzerland. The sequences were annotated by the basic local alignment search tool (BLAST) \[[@pone.0206214.ref032]\] for taxonomical identification. Entries were sorted by \"Max score\" and the top record used to annotate the genus and, if reliable, also the species classification for each bacterial strain. The sequence alignment tool MUSCLE \[[@pone.0206214.ref033]\] and SplitsTree 4.13 \[[@pone.0206214.ref034]\] were used to construct phylogenetic trees based on the BLAST annotations.

DNA extraction for 16S gene-based microbiota composition analysis {#sec013}
-----------------------------------------------------------------

DNA was extracted using the QIAamp Stool Mini Kit (Qiagen) with the following changes in the disruption and homogenization steps: 700μl of Buffer ASL, 2 spoons of small glass beads (0.1mm; Bio Spec products) and 1 spoon of large glass beads (0.5--0.75mm; Schieritz&Hauenstein, Laufen, Switzerland) were added to each stool sample. The samples were mixed using the TissueLyser (Qiagen) (3 min, 30Hz) and heated for 5 min at 95°C. Next, samples were again mixed using the TissueLyser (3 min, 30Hz), centrifuged at full speed for 1 min and the supernatants were transferred to a new 2 ml microcentrifuge tube. The pellet was suspended in 200 μl of Lysis Buffer (20mg/ml lysozyme (Sigma-Aldrich); 20mM Tris•HCl, pH 8.0; 2mM EDTA; 1.2% Triton) and incubated at 37°C for 30 min. Afterwards, 500 μl of Buffer ASL were added to each sample followed by mixing using the TissueLyser (3min, 30Hz) and heating the suspension for 5 min at 95°C. All samples were mixed again using the TissueLyser (3 min, 30Hz) and centrifuged at full speed for 1 min. The supernatants were transferred to the same 2 ml tube than used before. Half of an InhibitEX tablet (provided in Kit) was added to each sample and tubes were vortexed immediately until the tablet was completely suspended. Next, samples were incubated for 1 min at room temperature, centrifuged at full speed for 3 min and supernatants were transferred into a new 1.5 ml microcentrifuge tube. The samples were again centrifuged at full speed for 3 min. Meanwhile, 35 μl of proteinase K (provided in Kit) was added to a new 2 ml tube and supernatants from the previous centrifugation step were transferred to the 2 ml tube containing the proteinase K. 200 μl of Buffer AL were added and samples were vortexed for 15 sec and incubated at 70°C for 10 min. The next steps were performed according to the manual instructions. The final elution step was performed using 100 μl Buffer AE (pre-heated to 70°C) added to the membrane, then samples were incubated for 1 min at room temperature and centrifuged at full speed for 1 min to elute DNA.

Library preparation and sequencing for microbiota composition analysis {#sec014}
----------------------------------------------------------------------

The 16S rRNA gene libraries were produced using the NEXTflex® 16S V4 Amplicon-Seq Kit 2.0 (Barcodes 1--96; Bioo Scientific, Austin, Texas, USA). The input concentration of genomic DNA was adjusted to 30 ng/μl for each PCR reaction. The library preparation was performed following the manufacturer's instructions with the differences that the reaction volume was reduced to 25 μl and a modified primer pair was used for the first PCR reaction (final primer concentrations 0.5 μM). Instead of the original primer pair 515f-806r, the degenerative primer 515F (`5′-GTGYCAGCMGCCGCGGTAA-3′`) and 806rB (`5’-GGACTACNVGGGTWTCTAAT-3’`), as described in \[[@pone.0206214.ref035], [@pone.0206214.ref036]\] were used. The first PCR reaction was performed using Q5 High-Fidelity DNA Polymerase (BioConcept, NEB, Allschwil, Switzerland) under the following cycling conditions: 1) initial denaturation: 95°C for 4 min; 2) denaturation: 95°C for 30 sec; 3) annealing: 56°C for 30 sec; 4) extension: 72°C for 90 sec; 5) final extension: 72°C for 4 min. Cycles 2--4 were repeated 8 times. A negative control was included in each batch of PCR reactions, which showed no signs of amplification. After each reaction, the PCR products were cleaned up using AMPure XP magnetic beads (Beckman Coulter SA, Nyon, Switzerland). The clean PCR products were eluted in 20 μl of resuspension buffer and used in a second PCR reaction for producing multiplexed samples, respectively. The quantity of the amplicons was measured by a Qubit 3.0 fluorometer (Thermo Fisher Scientific). The quality of the amplicons was evaluated using a Fragment Analyzer (Advanced Analytical, Ankeny, IA, USA). The length of the barcoded amplicons was approximately 450 bp. The amplicons were pooled at equimolar concentrations and diluted to a final concentration of 60 ng DNA per 20 μl before loading on the Illumina MiSeq platform. Sequencing was performed at 2 x 250 bp read length at the Functional Genomics Center Zurich. All sequences obtained during this project have been deposited at the European Nucleotide Archive under the accession number: PRJEB28417

Microbiota composition analysis {#sec015}
-------------------------------

Initial analyses were performed using USEARCH (version 9.1.13) \[[@pone.0206214.ref037]\] using custom scripts that performed the following steps: paired reads were merged and quality-filtered using the *fastq_mergepairs* command with default settings. Merged reads were filtered using the *fastq_filter* command (-fastq_maxee 1.0) and only merged reads with perfect primer matches and a minimum length of 100 bp were selected. Sequences were de-replicated using the *fastx_uniques* and clustered into operational taxonomic units (OTUs) at 97% with chimera removal using the *cluster_otus* command (-minsize 2). OTU abundances for each sample were quantified using the *usearch_global* command (-strand both; -id 0.97). Taxonomic annotation was performed by matching OTU sequences against the SILVA database (version 128) using the *usearch_global* command (-id 0.90; -maxaccepts 20; -maxrejects 500; -strand both; -top_hits_only).

Further analyses were performed in RStudio (version 1.0.143 based on \[R\] version 3.3.3) using the libraries vegan \[[@pone.0206214.ref038]\] and ggplot2 \[[@pone.0206214.ref039]\]. Read counts were rarefied using the function *rrarefy* to 19\'000 reads per sample based on the sample with the lowest number of sequencing reads after excluding five samples that had too few reads. Shannon's diversity index for each sample was calculated using the *diversity* function. For performing a Principal Coordinate Analysis and for calculating intra-individual dissimilarity (grouped by time point or individual), Bray-Curtis distances were computed between pairs of samples using the *vegdist* function.

Statistical analysis {#sec016}
--------------------

Patient data with time curves for symptoms after lactulose/ sucrose exposure were analyzed using two-way repeated measures ANOVA (GraphPad Prism Version 7.02 La Jolla, CA, USA, [www.graphpad.com](http://www.graphpad.com/)). Correlation analysis for symptoms, hydrogen levels and Enterobacteriaceae counts was performed using Spearman R correlation of GraphPad Prism. Group comparisons for Enterobacteriaceae counts was done using the Mann-Whitney U test of GraphPad Prism. The sample size calculation was performed using G\*Power Version 3.1.9.2 \[[@pone.0206214.ref040]\]. A p-value of less than 0.05 was considered significant.

Microbiota composition analysis was done using USEARCH (version 9.1.13) \[[@pone.0206214.ref037]\] and R Studio (version 1.0.143 based on \[R\] version 3.3.3) with the libraries vegan \[[@pone.0206214.ref038]\] and ggplot2 \[[@pone.0206214.ref039]\] as described above. Significant differences between time points for each treatment group as well as phylum-level taxonomic abundances were calculated by paired Wilcoxon tests with FDR correction (0.05) for multiple testing. We also determined intra-individual dissimilarity using the Bray-Curtis distance and compared different sampling time points by paired Wilcoxon tests. For this analysis only individuals with samples from all three time points were included (n = 14 for sucrose, n = 13 for lactulose). To assess sources of variation in our data set, we tested the relative contribution of individuality and treatment to the overall variation of microbial compositions by permutational MANOVA (Permutations = 999).

Results {#sec017}
=======

Study population {#sec018}
----------------

Our study recruited 32 healthy volunteers ([Fig 1](#pone.0206214.g001){ref-type="fig"}), 18 out of 32 (56%) female of young age (median 25, IQR: 22.75--30, [Table 1](#pone.0206214.t001){ref-type="table"}). All individuals had normal bowel habits (frequency of bowel movements every 2--3 days to 2--3 times per day, median BSS 4), were non-smokers and most individuals followed a Western diet with regular physical activity. Medical history did not reveal relevant medical conditions or gastrointestinal complaints; medication included only analgetics, thyroid hormone replacements and hormonal contraception ([Table 1](#pone.0206214.t001){ref-type="table"}). Thus, we recruited a homogenous healthy study population.

Symptoms upon sucrose and lactulose ingestion {#sec019}
---------------------------------------------

Individuals were randomized with 17 individuals in the intervention group with lactulose ingestion and 15 individuals in the control group with sucrose ingestion, respectively ([Fig 2](#pone.0206214.g002){ref-type="fig"}). Following ingestion of the respective disaccharide, 14/17 (82%) of individuals in the lactulose group but only 3/15 (20%) of individuals in the control group reported physical symptoms. Within three hour of observation on a five-point scale, scores for bloating, diarrhea, borborygmi (bowel sounds) and abdominal pain of the lactulose group were significantly higher compared to the sucrose group (bloating: median 2 \[range 1--4\] vs. 1 \[1--2\], p = 0.0006; diarrhea: median 1 \[range 1--5\] vs. 1 \[1--1\], p = 0.0128; borborygmi: median 2 \[range 1--4\] vs. 1 \[1--2\], p = 0.0005; abdominal pain: median 1 \[range 1--3\] vs. 1 \[1--2\], p = 0.0163; [Fig 3](#pone.0206214.g003){ref-type="fig"}, [S1 Table](#pone.0206214.s005){ref-type="supplementary-material"}).

![Symptoms upon lactulose or sucrose ingestion.\
Severity of (A) bloating, (B) stool alterations, (C) borborygmi and (D) abdominal pain was rated by individual participants according to the following scale: 1---no symptoms, 2 --symptoms which can be ignored), 3 --symptoms which cannot be ignored, but don\'t affect daily activities, 4 --symptoms affecting daily activities, 5 --symptoms dominating and severely inhibiting daily activities. \*p\<0.05, \*\*\*p\<0.001; Two-way repeated measures ANOVA.](pone.0206214.g003){#pone.0206214.g003}

On separate questioning, 13 out of 17 individuals reported diarrhea (defined as ≥3 bowel movements within 6 hours after lactulose intake); diarrhea was accompanied by loose stool consistency (Bristol stool scale, BSS ≥5 in all individuals with diarrhea). 5 of those reported ≥4 bowel movements with BSS 7. The remaining 4 out of 17 individuals did not respond to lactulose treatment with no defecation during 6 hours in 3 participants and 1 defecation BSS 5 in the remaining participant. No diarrhea was observed in the control (sucrose).

After lactulose exposure, H~2~ levels in expiratory air gradually increased for the next 90 min and remained at significantly higher level with lactulose compared to sucrose (p\<0.001) until the end of the observation period (180 min, [Fig 4](#pone.0206214.g004){ref-type="fig"}). H~2~ levels varied widely (0--146 ppm); for three individuals of the lactulose intervention group, H~2~ levels in expiratory air never increased for more than 20 ppm over baseline; these individuals are by definition H~2~ non-producers \[[@pone.0206214.ref010]\].

![Hydrogen and methane levels and symptoms following lactulose ingestion.\
(A) Hydrogen levels in parts per million (ppm) following lactulose or sucrose (control) ingestion. \*\*\*p \< 0.001; two-way repeated measures ANOVA. (B) Correlation between maximum (max) hydrogen and methane levels. (C) Correlation between maximum hydrogen levels and number of defecations during 6 hours following lactulose or sucrose ingestion. (D) Correlation between maximum hydrogen levels (max) and stool consistency (Bristol stool scale) following lactulose or sucrose ingestion. r: Spearman R correlation coefficient.](pone.0206214.g004){#pone.0206214.g004}

For 14 out of 32 individuals (5 in the sucrose group, 9 in the lactulose group) methane (CH~4~) measurements were also taken ([Fig 4B](#pone.0206214.g004){ref-type="fig"}); for technical reasons, only the last 14 individuals included into our study could be tested. However, only a single individual had increased CH~4~ levels at baseline (15 ppm) and for no individual CH~4~ levels exceeded 10 ppm over baseline. For the three H~2~ non-producers no CH~4~ measurements were available.

H~2~ levels in expiratory air correlated with number of defecations (p = 0.024, [Fig 4C](#pone.0206214.g004){ref-type="fig"}); correlation analysis with stool consistency (BSS) revealed a non-significant trend (p = 0.052, [Fig 4D](#pone.0206214.g004){ref-type="fig"}), suggesting that the intestinal response to lactulose was associated with H~2~ production.

Bacterial growth in stool samples of lactulose and sucrose treated subjects {#sec020}
---------------------------------------------------------------------------

We tested whether lactulose ingestion and exposure of the intestine to excess H~2~ increases levels of *E*. *coli* and related Enterobacteriaceae in stool samples. Consistency of collected stool samples (as judged by in inspection of collected material) was similar at all time points (day -1, day 1 and day 14), arguing against significant confounding by sample dilution. Stool samples were plated on selective media to quantify *E*. *coli* one day before (baseline), one day after, and two weeks after disaccharide exposure ([Fig 5](#pone.0206214.g005){ref-type="fig"}). At all time points, no difference in bacterial numbers could be detected ([Fig 5A--5C](#pone.0206214.g005){ref-type="fig"}). Variation within the two groups was high, with bacterial densities ranging from 3 x 10^2^ to 10^9^ colony forming units (CFU) per g fecal sample in the control group and 2 x 10^2^ to 8 x 10^8^ CFU per g in the lactulose group ([Fig 5A--5C](#pone.0206214.g005){ref-type="fig"}).

![*E*. *coli* counts in stool samples at different time points.\
(A-C) Stool samples were plated on selective agar without antibiotics to quantify *E*. *coli* counts (CFU). ns = not significant; Mann-Whitney U test. (D-F) Correlations of *E*. *coli* counts within the feces collected at different time points. ns: not significant; \*p \< 0.05 = significant; \*\*p \< 0.01; \*\*\*\*p \< 0.001; r: Spearman R correlation coefficient. Dashed lines = detection limit.](pone.0206214.g005){#pone.0206214.g005}

CFU counts remained stable over time and no difference for time points could be detected in a paired analysis (p\>0.05 for all comparisons, Wilcoxon matched pairs signed-rank test). We found significant correlations of the number of CFUs at baseline, day 1 and day 14 in the group with lactulose treatment ([Fig 5D--5F](#pone.0206214.g005){ref-type="fig"}), indicating stability of *E*. *coli* population size over time and upon lactulose perturbation.

Considering the H~2~ metabolism in *E*. *coli* and other organisms (e.g. *S*. Typhimurium, *Yersinia*, *Campylobacter*, *Shigella* \[[@pone.0206214.ref017]--[@pone.0206214.ref021]\] our data argue against a pronounced effect of increased H~2~ levels on the growth of potential invading enteropathogens. In line with this interpretation, the number of CFU at the day after lactulose exposure (or the ratio of CFU between time points) did not correlate with maximum H~2~ levels in expiratory air at the intervention day (Figure A in [S1 Fig](#pone.0206214.s003){ref-type="supplementary-material"}).

Number of CFUs or ratios of CFUs between days also did not correlate with number of defecations after lactulose exposure (Figure B in [S1 Fig](#pone.0206214.s003){ref-type="supplementary-material"}). We noted a positive correlation between CFU and stool consistency (BSS) and the ratio of CFUs on day -1: day 1 in the control group but not in the lactulose group (Figure C in [S1 Fig](#pone.0206214.s003){ref-type="supplementary-material"}).

No *Salmonella enterica* colonies were detected in any of the stool samples, as judged from the absence of color-less colonies on the MacConkey agar plates and 16S sequencing in ambiguous cases.

Phylogenetic analysis of stool isolates {#sec021}
---------------------------------------

To confirm species affiliation of isolated Enterobacteriaceae, bacterial strains from 30 participants at one day after treatment were analyzed by sequencing the 16S rRNA gene. Sequences were classified using the basic local alignment search tool (BLAST). All bacteria isolated from MacConkey agar were found to belong to the family of Enterobacteriaceae with a large cluster of 20 *E*. *coli* related species (20 *E*. *coli*, 5 *E*. *coli*/ *Shigella*) and a distantly related cluster of 2 *Klebsiella*, 2 *Enterobacter* and 1 *Citrobacter* species ([Fig 6](#pone.0206214.g006){ref-type="fig"}).

![Phylogenetic tree of Enterobacteriaceae strains isolated one day after treatment.\
Tree showing the relatedness between bacterial strains (n = 30) isolated from participant samples one day after treatment with sucrose (grey) or lactulose (orange). 16S rRNA sequences were annotated by BLAST and aligned using MUSCLE and SplitsTree. *Escherichia/Shigella* thereby indicates a strain with a sequence compatible with both, *E*. *coli* and *Shigella*. Horizontal lines indicate nucleotide substitutions per site. Please note that *E*. *coli* and *Shigella* are extremely closely related. Thus, the detection of *Escherichia/Shigella*-like sequences does [not]{.ul} imply that *Shigella* spp. were present in the stools of any of the participants.](pone.0206214.g006){#pone.0206214.g006}

Antibiotic resistance {#sec022}
---------------------

Annotated human bacterial isolates were tested for resistance against different antibiotics. Seven antibiotics (imipenem, cefepime, gentamicin, kanamycin, ciprofloxacin, and trimethoprim/ sulfamethoxazole) from 5 classes (carbapenems, cephalosporins, aminoglycosides, fluoroquinolone and folic acid synthesis inhibitors) were chosen according to known genetic determinants of resistance in Enterobacteriaceae to evaluate resistance status in environmental settings \[[@pone.0206214.ref027]\].

All bacterial strains tested were susceptible to imipenem, cefepime, and kanamycin ([S2 Table](#pone.0206214.s006){ref-type="supplementary-material"}). Bacterial resistance against ampicillin was common (11 out of 30 strains, 37%) followed by sulfamethoxazole/trimethoprim (7 out of 30 strains, 23%), ciprofloxacin (2 out of 30 strains, 7%) and gentamicin (1 out of 30 strains, 3%). Five bacterial strains were resistant to two or more antibiotics ([S2 Table](#pone.0206214.s006){ref-type="supplementary-material"}). No extended spectrum beta-lactamase producing strains were identified.

Stability of microbiota upon lactulose exposure {#sec023}
-----------------------------------------------

We used 16S rRNA gene sequencing to analyze the taxonomic composition of the intestinal microbiota after lactulose challenge. Overall, we observed no significant difference in bacterial diversity between lactulose and sucrose treated individuals at day 1 and day 14 compared to pre-treatment conditions ([Fig 7A](#pone.0206214.g007){ref-type="fig"}). The microbiota composition was also highly similar between lactulose and sucrose treatment. An example for phylum level compositions is provided in [Fig 7B](#pone.0206214.g007){ref-type="fig"}. The mean relative abundance of Enterobacteriaceae was 0.4% (interquartile range 0.07% - 0.6%) of all intestinal bacteria detected by 16S sequencing. No significant alteration in the relative abundance of the family Enterobacteriaceae and genus *Escherichia-Shigella* (represented by a single OTU with a 100% sequence match to *E*. *coli*) was detected neither within nor between treatment groups (false discovery rate (FDR)-corrected Wilcoxon tests) and sampling time points within treatments (paired FDR-corrected Wilcoxon tests, [S2 Fig](#pone.0206214.s004){ref-type="supplementary-material"}).

![A single dose of lactulose (50 g) has no significant effect on fecal bacterial community structure a day or two weeks after treatment.\
(A) Shannon diversity index shows no significant change (paired Wilcoxon test, P\>0.05) one day or two weeks after treatment (sucrose n = 15, lactulose n = 17) for each group. (B) Relative phylum abundance before (day -1) and after (day 1 and day 14) ingestion of sucrose (n = 15) or lactulose (n = 17). Colors indicate bacterial phyla, none on which were significantly different between time points. (C) Principal coordinate (PCo) analysis of microbiota composition with symbols and colors denoting sampling time point and treatment (sucrose, lactulose), respectively. The numbers denote the different individuals with samples from all three time points. (D) Intra-individual dissimilarity (Bray-Curtis) of microbial composition in samples collected at different sampling time points (day---1 to 1, day -1 to 14 and day 1 to 14) and treatments with sucrose (n = 14) and lactulose (n = 13). Only individuals with samples from all three time points with a rarefaction cut-off of \>19\'000 were included in the intra-individual dissimilarity analysis (Bray-Curtis) of the microbiota composition. No significant shifts in bacterial composition were detected between different time points (paired Wilcoxon test, p\>0.05). (E) Intra-individual dissimilarity (Bray-Curtis) of fecal microbial composition between the three sampling time points. The color key indicates the Bristol stool scale (BSS) of the same day (i.e., day 0) and after the lactulose/ sucrose challenge. The grey dots show maximal hydrogen levels in parts per million (ppm) following lactulose or sucrose ingestion.](pone.0206214.g007){#pone.0206214.g007}

We observed intra-individual shifts in the dissimilarity of microbial composition between the different sampling time points (days -1, 1, 14). Nevertheless, the shifts were similar in size for lactulose and sucrose treated individuals. Furthermore, we did not observe any clustering of samples by treatment (principal coordinate (PCo); analysis [Fig 7C](#pone.0206214.g007){ref-type="fig"}). Similarly, we detected no significant intra-individual dissimilarity changes before and after lactulose/ sucrose ingestion ([Fig 7D](#pone.0206214.g007){ref-type="fig"}). Additionally, there was no correlation between intra-individual dissimilarity (i.e. dissimilarity between time points) and BSS or H~2~ levels ([Fig 7E](#pone.0206214.g007){ref-type="fig"}).

Given the absence of a strong treatment-related effect on microbial composition, we sought to assess the sources of variation in our data set. To this end, we tested the relative contribution of individuality and treatment to the overall variation of microbial compositions (permutational MANOVA). For both treatments, we found individual variations but not treatment to explain the vast majority of the variation (effect of individuals: sucrose group---R^2^: 0.77, p = 0.001; lactulose group---R^2^: 0.82, p = 0.001; effect of treatment: sucrose group--R^2^: 0.01 n.s.; lactulose group--R^2^: 0.007, n.s.).

Discussion {#sec024}
==========

We performed a placebo controlled randomized controlled study to test effects of a single dose lactulose challenge on gastrointestinal microbiota composition and wellbeing in a homogenous group of young healthy individuals. The following key observations were made: i) Lactulose caused an increase in H~2~ levels in expiratory air and diarrhea in the vast majority of individuals in the lactulose group. ii) In the lactulose group, H~2~ levels correlated with severity of diarrhea (i.e. number of defecations). iii) Lactulose exposure did not increase the number of CFU of *E*. *coli* in stool samples collected 1 day after exposure. iv) The microbiota composition at that time point was also not significantly affected by single-dose lactulose challenge compared to the sucrose control, indicating that individual day-to-day variations of the microbiota are much stronger than the perturbation by a single 50 g lactulose ingestion.

Effectiveness of a single dose lactulose as a laxative {#sec025}
------------------------------------------------------

Usage of lactulose for the treatment of acute or chronic constipation is well established \[[@pone.0206214.ref041]\]. Recent randomized controlled trials used lactulose as a standard treatment for comparative testing against sodium polyethylene glycol (PEG) \[[@pone.0206214.ref042], [@pone.0206214.ref043]\], sodium picosulfate \[[@pone.0206214.ref042]\] and Chinese or Pakistan herbal medicine \[[@pone.0206214.ref044], [@pone.0206214.ref045]\]. Effects of PEG were stronger than lactulose in a Cochrane meta-analysis \[[@pone.0206214.ref046]\] and PEG or liquid paraffin were more effective in children \[[@pone.0206214.ref047]\] even though these differences are small and possibly not clinically relevant. Cost-effectiveness of PEG and lactulose was virtually identical \[[@pone.0206214.ref048]\]. Interestingly, lactitol might be similarly effective, but more palatable with lesser side effects than lactulose \[[@pone.0206214.ref049]\].

We are not aware of a recent placebo-controlled randomized controlled trial for one-time application of lactulose in young healthy individuals. Thus, our study provides valuable information on the effectiveness of lactulose in healthy individuals. We observed diarrhea (i.e. ≥3 bowel movements in 6 hours) in 14 out of 17 (82%) of healthy participants ingesting lactulose which was accompanied by at least moderate borborygmi, bloating, flatulence (14 out of 17, 82% for each symptom) and abdominal pain (8 out of 17, 47%).

Methane levels in expiratory air and H~2~ non-producers {#sec026}
-------------------------------------------------------

A fraction of patients and healthy individuals contain a methanogenic organism such as *Methanobrevibacter smithii* \[[@pone.0206214.ref050]\]. Hydrogenotrophic methanogens use 4 molecules of H~2~ and 1 molecule of carbon dioxide (CO~2~) to produce 1 molecule of methane (CH~4~) \[[@pone.0206214.ref051]\]. Due to this additional metabolization step, the CH~4~ peak will be delayed and due to the 4:1 ratio of H~2~ and CH~4~, the methane peak will be at a lower level compared to H~2~. Therefore, a cut-off of 10 ppm for CH~4~ is suggested \[[@pone.0206214.ref010]\]. Furthermore, individuals with a methanogenic microbiota usually have increased levels of CH~4~ even at baseline, but fail to produce measurable H~2~ upon appropriate testing \[[@pone.0206214.ref010]\]. In our analysis, methane measurements from only 14 individuals were available and only for one person, methane levels exceeded the threshold of 10 ppm. Our study included three H~2~ non-producers (18%) without any increase in H~2~ levels, well within the expected range of 2--43% in healthy individuals or patients \[[@pone.0206214.ref052]\]. However, no methane measurements for these individuals are available.

Correlation of symptoms with H~2~ levels {#sec027}
----------------------------------------

The healthy human intestine contains 30--200 ml (average 100 ml) gas, which mainly consists of H~2~, CO~2~ and CH~4~ \[[@pone.0206214.ref010], [@pone.0206214.ref053]\]. Both, H~2~ and CH~4~ are exclusively produced by the bacterial microbiota \[[@pone.0206214.ref050]\].

Our study found a significant association of peak H~2~-levels with severity of diarrhea upon lactulose challenge in healthy individuals, arguing for a relationship between H~2~-production and symptoms after lactulose challenge. The association of results of the lactulose breath test with a diagnosis of irritable bowel syndrome (IBS) or IBS symptoms is controversial. A large analysis failed to find differences in IBS patients vs. healthy controls \[[@pone.0206214.ref054]\]. However, the H~2~ response in the lactulose breath test was related to bloating in IBS patients \[[@pone.0206214.ref055]--[@pone.0206214.ref057]\]. Similarly, a recent study using a large cohort of Chinese IBS patients found both, high H~2~ levels (area under the curve) in breath tests and visceral hypersensitivity to be risk factors for bloating and borborygmi and overall symptom burden \[[@pone.0206214.ref058]\].

Methane data were available only for a subset of participants and no correlation with symptoms could be established. Previous studies confirmed an association of methane levels in expiratory air with constipation \[[@pone.0206214.ref059], [@pone.0206214.ref060]\] and the severity of constipation correlated with methane levels \[[@pone.0206214.ref059]\].

Stability of the microbiota upon single-dose lactulose challenge {#sec028}
----------------------------------------------------------------

In our study, no significant effects of a single dose of 50 g lactulose on microbiota composition could be detected after 1 day or after 14 days ([S2 Fig](#pone.0206214.s004){ref-type="supplementary-material"}). The number of *E*. coli counts in our study (10^4^ to 10^8^ cfu/g feces, [Fig 5](#pone.0206214.g005){ref-type="fig"}) and the mean relative abundance of Enterobacteriaceae (0.4% of all intestinal bacteria detected by 16S sequencing) are well in line with numbers described in the literature \[[@pone.0206214.ref061]--[@pone.0206214.ref065]\], indicating a normal intestinal microbiota before and after lactulose challenge. Previous diet intervention studies showed that short-term macronutrient shifts reversibly alter gut microbiota composition within 24 hours even though broad patterns of microbiota composition similarities (enterotypes) remain stable \[[@pone.0206214.ref022]--[@pone.0206214.ref025]\]. Our PCo analysis showed that lactulose challenge did not significantly alter the microbial composition since similar patterns of small-scale shifting were observed for lactulose and sucrose, alike (day 1 and day 14). Instead, our data argue for a stability of microbiota compositions with daily variations dominating over changes due to a single intervention with 50 g lactulose, even though diarrhea was observed in the majority of individuals. However, the data of this study provides no information about short-term microbiota compositional changes immediately after lactulose challenge, nor about site-specific effects within the small intestine or the right-sided colon.

Effects of lactulose on the risks for intestinal infections {#sec029}
-----------------------------------------------------------

Prebiotics are food ingredients, which are neither digested nor degraded in the stomach or small intestine, but fermented by the gut microbiota, leading to a selective stimulation of the growth of certain intestinal bacteria and may thereby reap potential benefits for the host \[[@pone.0206214.ref066]\]. Lactulose, along with inulin and other oligosaccharides are considered prebiotics and *Lactobacillus* and *Bifidobacterium* are considered significant target genera for the associated prebiotic effects \[[@pone.0206214.ref066], [@pone.0206214.ref067]\].

Since over 50 years, lactulose has been considered the "bifidus factor", increasing fecal *Bifidobacterium* counts \[[@pone.0206214.ref068]\]. A number of subsequent studies have confirmed increased intestinal content of *Bifidobacterium* \[[@pone.0206214.ref069]--[@pone.0206214.ref075]\] and *Lactobacillus* \[[@pone.0206214.ref069], [@pone.0206214.ref072]\] in human stool samples upon lactulose exposure. Those studies relied on conventional microbiological techniques and did not address the overall composition of the intestinal microbiota. Furthermore, in contrast to our study, lower dosages of lactulose (5--20 g) and longer exposure times (4--8 weeks) were used, potentially explaining differences to our results. In fact, effects on *Bifidobacterium* stool densities were weaker and not significantly different from controls in an 8-day study \[[@pone.0206214.ref076]\]. However, short-term effects of lactulose on the intestinal microbiota have not been tested previously. No "bifidus factor" effects were observed in our study and differences in the time of lactulose exposure might explain this discrepancy.

Fermentation of lactulose is not limited to *Lactobacillus* and *Bifidobacterium*. Glucosidases and bacterial transporters for lactulose are abundant in a large number of intestinal bacteria including *Cronobacter*, *Enterococcus*, *Escherichia*, *Klebsiella*, *Pseudomonas*, and *Streptoccoccus* spp., which were able to grow on lactulose as the sole carbon source \[[@pone.0206214.ref013]\]. One recent study addressed effects of feeding mice with lactulose for two weeks: The authors noted a decrease in pH and an increase in short chain fatty acids in the colon. In the same mice, an increase in Proteobacteria and Actinobacteria including *Bifidobacterium* and a decrease in Firmicutes was observed. An increase in *Helicobacter* and *Akkermansia* spp. content was interpreted to be secondary to increased mucin production. Similar to our study, no increase in *E*. *coli* content was observed \[[@pone.0206214.ref077]\]. These changes were accompanied by an increase in *Bifidobacterium*, *Lactobacillus* spp. and Enterobacteriaceae. In our study, we found a remarkable stability of the microbiota upon lactulose perturbation with 50 g lactulose resulting in diarrhea in \>80% of participants. In fact, day to day variation in the control group were as big as variations in the experimental group and only approximately 3% of the variance can be explained by lactulose treatment (not shown).

Effects of lactulose on growth of intestinal pathogens are controversial. *In vitro* co-cultures of human intestinal *Lactobacillus* isolates with *E*. *coli*, *Salmonella enteritidis* or *Vibrio cholerae*, demonstrated reduced growth of the enteric bacterial pathogens \[[@pone.0206214.ref078]\]. Case series also demonstrated therapeutic effects of lactulose treatment for human carriers of non-typhoid *Salmonellae* \[[@pone.0206214.ref079]\] and a temporary reduction of *Shigella* excretion in carriers \[[@pone.0206214.ref080]\]. Application of lactulose was suggested to decrease the number of urinary tract infections \[[@pone.0206214.ref081]\]. However, in a rat model of *Salmonella enteritides* infection, lactulose inhibited *S*. Typhimurium colonization, but stimulated bacterial translocation and intestinal inflammation \[[@pone.0206214.ref082]\].

In our study, we were aiming to establish an experimental model for improved growth conditions for Enterobacteriaceae. *In vivo* data from our group with a murine colitis model suggested that the initial growth of *S*. Typhimurium within the first day depended on the presence of enzymes enabling hydrogen utilization \[[@pone.0206214.ref018]\]. Better growth conditions for *S*. Typhimurium would suggest a higher susceptibility for bacterial infections upon lactulose exposure. This might be relevant for patients with liver cirrhosis who are highly susceptible to bacterial infections \[[@pone.0206214.ref083]\] and for whom lactulose remains the first-line drug for treatment and prevention of hepatic encephalopathy \[[@pone.0206214.ref009]\].

In our study, we did not find an increase in *E*. *coli* levels one day after lactulose application even though *E*. *coli* could potentially benefit from H~2~ produced upon lactulose ingestion. In agreement with our results, no clinical data support an increased risk of Enterobacteriaceae infections upon lactulose exposure. One reason for this could be that intrinsic *E*. *coli* are part of metabolic networks in biofilms in the large intestine and might still depend on metabolic contributions from other bacteria (according to the \"Restaurant\" hypothesis) \[[@pone.0206214.ref084]\], which limits any stimulatory effects of H~2~ and further studies for the metabolization of lactulose in the intestine are warranted.

In summary, exposure with a single lactulose dose leads to diarrhea in \>80% of healthy individuals but not to an increase in *E*. *coli* CFU and no microbiota shifts. A single lactulose dose is therefore unlikely to significantly improve growth conditions of H~2~-consuming enteropathogens such as *S*. Typhimurium in the human gut.
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###### Study protocol.

Detailed protocol of all study procedures including lactulose and sucrose treatment.
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Click here for additional data file.

###### CONSORT statement.
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###### Relationship of bacterial counts with hydrogen levels and clinical symptoms.

\(A\) Correlation analysis between maximum (max) hydrogen levels and bacterial loads within feces collected one day after treatment. (B) Correlation analysis between bacterial loads within feces collected one day after treatment and the number of defecations during 6 hours following lactulose or sucrose ingestion. (C) Correlation between bacterial loads within feces collected one day after treatment and Bristol stool scale during 6 hours following lactulose or sucrose ingestion. p \> 0.05 = not significant; \*\*p \< 0.01 = significant; Spearman R correlation. Dashed lines = detection limit.
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Click here for additional data file.

###### The abundance of Enterobacteriaceae (family) and *Escherichia-Shigella* (genus) do not differ between time points and treatments.

\(A\) Taxonomic annotation of five OTUs of the family of Enterobacteriaceae are shown, one of which belongs to the genus *Escherichia*/ *Shigella*, which had a 100% sequence match to *Escherichia coli*. (B) The relative abundance of members of the genus *Escherichia-Shigella* (striped, upper right part) and the family Enterobacteriaceae (lower left part) show no significant (p\<0.05) differences according to treatment (lactulose vs. sucrose) or between time points (paired Wilxocon test, with FDR correction). The numbers in the boxes are FDR corrected p-values for the group comparisons. The color key indicates the difference \[%\] in mean relative abundance (percentage of all bacteria) between two groups r*i*--c*j*, where r*i* represents the mean relative abundance of the group identified by the row label and c*j* the mean relative abundance of the group identified by the column label. Difference in abundance is expressed as mean difference of the percentages.
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###### Antibiotic resistances of isolated *E*. *coli* strains.

Dark grey indicates resistance against the respective antibiotics, medium grey indicates intermediate resistance against the tested antibiotic (this depends on the antibiotic) and light grey means susceptibility to the antibiotic.

(DOCX)
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Click here for additional data file.
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